logo-loader
viewPrecipio Inc

Precipio to provide several hospitals in Cairo, Egypt with diagnostics services

The New Haven, Connecticut-based specialty cancer diagnostics firm said the contract is expected to generate more than $1.5 million in annual revenue

Lab worker works with a microscope
The Egyptian hospitals will license Precipio’s proprietary technologies to provide liquid biopsy and hematologic molecular testing

Precipio Inc (NYSE:PRPO), a specialty cancer diagnostics firm, announced Monday it has signed a services contract with several hospitals in Cairo, Egypt that could be worth more than $1.5 million.

The New Haven, Connecticut-based company did not name the management group nor did it reveal the contract’s total amount.

Shares of Precipio jumped 9% to $5.24 following news of the contract.

WATCH: Precipio in talks with international health care systems to expand reach

Precipio said the Cairo hospitals will send patient biopsies for primary diagnosis and secondary consultation. In addition, the contract calls for establishing laboratory operations in Egypt that will license Precipio’s proprietary technologies to provide liquid biopsy testing using ICE-COLD PCR technology, and HemeScreen for hematologic molecular testing.

The announcement of Egyptian contract is part of the company’s strategy to expand internationally with a focus on Asia, Europe, the Middle East and South America. “The international segment of our business is going to be a valuable contributor to our revenues, margins and cash flow in the coming quarters,,” said CEO Ilan Danieli.

The contract also comes as Precipio regained compliance with Nasdaq listing requirements to maintain a minimum bid price of $1 a share. The company on Friday said it would execute a 1:15 reverse stock split of its common stock, and the post-spilt took effect Monday, helping to boost the sare price.

Contact the author: [email protected]

Follow him on Twitter @patrickmgraham

Quick facts: Precipio Inc

Price: 2.18 USD

NASDAQ:PRPO
Market: NASDAQ
Market Cap: $16.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 day, 19 hours ago

2 min read